Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 4/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 4/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584474 | 0.85 | CHRNA4 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL17953045 | 0.83 | CHRNA4 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2031616 | 0.83 | CHRNA4 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL9636772 | 0.80 | CHRNB2 (0.67) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL584402 | 0.78 | CHRNA4 (0.74) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL10409323 | 0.78 | CHRNA4 (0.64) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL14676930 | 0.77 | CHRNB2 (0.71) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL6738910 | 0.76 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL6319408 | 0.76 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL12744721 | 0.75 | CHRNB2 (0.60) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0665014-B1 | 3-benzoyl-3,7-diazabicyclo(3,3,1)nonane anti-arrhythmic compounds | SOLVAY PHARM GMBH (DE) | 1997-09-03 | — | — | EP | claimed |
| US-5532251-A | ANALGESICS AND CARDIOVASCULAR DISORDERS | KALI-CHEMIE PHARMA GMBH (DE) | 1996-07-02 | — | — | US | claimed |
| JP-7252152-A | — | — | None | — | — | JP | disclosed |
| US-20160214983-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-07-28 | — | — | US | disclosed |
| US-6602880-B2 | 3-phenyl-3,7-diazabicyclo[3.3.1] nonane compounds, process for preparing them, pharmaceutical compositions containing them and use thereof to inhibit cardiac arrhythmia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| US-20030109541-A1 | 3-Phenyl-3,7-diazabicyclo[3.3.1] nonane compounds, process for preparing them, pharmaceutical compositions containing them and use thereof to inhibit cardiac arrhythmia | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-06-12 | — | — | US | disclosed |
| EP-0665014-B1 | 3-benzoyl-3,7-diazabicyclo(3,3,1)nonane anti-arrhythmic compounds | SOLVAY PHARM GMBH (DE) | 1997-09-03 | — | — | EP | disclosed |
| US-5532251-A | ANALGESICS AND CARDIOVASCULAR DISORDERS | KALI-CHEMIE PHARMA GMBH (DE) | 1996-07-02 | — | — | US | disclosed |
| US-5532251-A | ANALGESICS AND CARDIOVASCULAR DISORDERS | KALI-CHEMIE PHARMA GMBH (DE) | 1996-07-02 | — | — | US | disclosed |
| US-5532251-A | ANALGESICS AND CARDIOVASCULAR DISORDERS | KALI-CHEMIE PHARMA GMBH (DE) | 1996-07-02 | — | — | US | disclosed |
| CN-1110556-A | Pharmaceutical containg 3-benzoyl-3,7-diazabicydo [3.3.1]nonan compound | KALI CHEMIE PHARMA GMBH (DE) | 1995-10-25 | — | — | CN | disclosed |
| JP-H07252152-A | ANTIARRHYTHMIC AGENT AND ITS PRODUCTION | KALI CHEM PHARMA GMBH | 1995-10-03 | — | — | JP | disclosed |
| EP-0665014-A1 | 3-benzoyl-3,7-diazabicyclo(3,3,1)nonane anti-arrhythmic compounds | Kali-Chemie Pharma GmbH (DE) | 1995-08-02 | — | — | EP | disclosed |
| EP-0665014-A1 | 3-benzoyl-3,7-diazabicyclo(3,3,1)nonane anti-arrhythmic compounds | Kali-Chemie Pharma GmbH (DE) | 1995-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214983-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS | TBXA2R, PDGFRA, TBXAS1 | CHRNB2 2300/4885CHRNB4 2358/4885CHRNA3 701/4885 |
| US-20030109541-A1 | 3-Phenyl-3,7-diazabicyclo[3.3.1] nonane compounds, process for preparing them, pharmaceutical compositions containing them and use thereof to inhibit cardiac arrhythmia | SCN1B, KCNH1, SCN2B | CHRNB2 1089/4885CHRNB4 1354/4885CHRNA3 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.